Time-course of Mitochondrial Biogenic Gene and Protein Expression in Exercised Human Skeletal Muscle

March 2, 2020 updated by: Brendon Gurd, PhD

Impact of Exercise Intensity on the Time-course of Mitochondrial Biogenic Gene and Protein Expression in Human Skeletal Muscle.

This study examines the impact of exercise intensity on the 12-hour time-course of mitochondrial biogenic gene and protein expression in human skeletal muscle. Briefly, participants will perform two experimental sessions involving an acute bout of work-matched low- or high-intensity interval cycling exercise in a randomized crossover fashion, two weeks apart. Skeletal muscle biopsies will be obtained from the vastus lateralis (3 from each leg) before and 1, 3, 6, 9, and 12 hours post-exercise. Changes in the expression of various transcription factors and mitochondrial proteins will be examined at the mRNA and protein level to determine the time-course of changes in these factors differs between exercise protocols of different intensities.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

10

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Ontario
      • Kingston, Ontario, Canada, K7L3N6
        • Recruiting
        • School of Kinesiology and Health Studies
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 30 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • recreationally active (no more than three hours of structured weekly physical activity)
  • not currently involved in a systematic training program for improving cardiorespiratory fitness, muscular strength, and/or sport-specific skills
  • body mass index < 30 kg/m2

Exclusion Criteria:

  • presence of cardiometabolic disease
  • taking regular prescription medication for the treatment of cardiometabolic disease
  • current cigarette smoker

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: low-intensity exercise - high-intensity exercise
low-intensity exercise session followed by a high-intensity exercise session separated by a minimum of 14 days
Other: LO
Participants will perform an acute bout of low-intensity cycling (11 x 1 min intervals at ~73% of peak aerobic work rate interspersed with 1 min recovery periods)
Other: HI
Participants will perform an acute bout of high-intensity cycling (8 x 1 min intervals at ~100% of peak aerobic work rate interspersed with 1 min recovery periods)
Experimental: high-intensity exercise - low-intensity exercise
high-intensity exercise session followed by a low-intensity exercise session separated by a minimum of 14 days
Other: LO
Participants will perform an acute bout of low-intensity cycling (11 x 1 min intervals at ~73% of peak aerobic work rate interspersed with 1 min recovery periods)
Other: HI
Participants will perform an acute bout of high-intensity cycling (8 x 1 min intervals at ~100% of peak aerobic work rate interspersed with 1 min recovery periods)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in peroxisome proliferator activated receptor (PPAR) gamma co-activator 1-alpha (PGC-1α) messenger ribonucleic acid (mRNA) expression
Time Frame: before exercise to 1, 3, 6, 9, and 12 hours post-exercise
PGC-1α gene expression (indirect indicator of PGC-1α activity). Transcriptional co-activator involved in the control of mitochondrial biogenesis.
before exercise to 1, 3, 6, 9, and 12 hours post-exercise

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in PGC-1α protein content
Time Frame: before exercise to 1, 3, 6, 9, and 12 hours post-exercise
PGC-1α protein content
before exercise to 1, 3, 6, 9, and 12 hours post-exercise
Change in nuclear factor-erythroid 2 like 2 (Nrf2) mRNA expression
Time Frame: before exercise to 1, 3, 6, 9, and 12 hours post-exercise
Nrf2 gene expression (indirect indicator of Nrf2 activity). Transcription factor involved in the control of mitochondrial biogenesis.
before exercise to 1, 3, 6, 9, and 12 hours post-exercise
Change in Nrf2 protein content
Time Frame: before exercise to 1, 3, 6, 9, and 12 hours post-exercise
Nrf2 protein content
before exercise to 1, 3, 6, 9, and 12 hours post-exercise
Change in PPAR-beta mRNA expression
Time Frame: before exercise to 1, 3, 6, 9, and 12 hours post-exercise
PPAR-beta gene expression (indirect indicator of PPAR-beta activity). Transcription factor involved in the control of mitochondrial biogenesis.
before exercise to 1, 3, 6, 9, and 12 hours post-exercise
Change in estrogen related receptor (ERR)-gamma mRNA expression
Time Frame: before exercise and 1, 3, 6, 9, and 12 hours post-exercise
ERR-gamma gene expression. Transcription factor involved in the control of mitochondrial biogenesis.
before exercise and 1, 3, 6, 9, and 12 hours post-exercise
Change in leucine-rich pentatricopeptide repeat containing protein 130 (LRP130) mRNA expression
Time Frame: before exercise to 1, 3, 6, 9, and 12 hours post-exercise
LRP130 gene expression. Transcriptional co-activator and RNA-binding protein involved in the transcriptional control and stabilization of mitochondrial mRNAs
before exercise to 1, 3, 6, 9, and 12 hours post-exercise
Change in LRP130 protein content
Time Frame: before exercise and 1, 3, 6, 9, and 12 hours post-exercise
LRP130 protein content
before exercise and 1, 3, 6, 9, and 12 hours post-exercise
Change in nuclear respiratory factor-1 (NRF-1) mRNA expression
Time Frame: before exercise to 1, 3, 6, 9, and 12 hours post-exercise
NRF-1 gene expression. Transcription factor involved in the control of mitochondrial biogenesis.
before exercise to 1, 3, 6, 9, and 12 hours post-exercise
Change in NRF-1 protein content
Time Frame: before exercise to 1, 3, 6, 9, and 12 hours post-exercise
NRF-1 protein content
before exercise to 1, 3, 6, 9, and 12 hours post-exercise
Change in mitochondrial transcription factor A (TFAM) mRNA expression
Time Frame: before exercise and 1, 3, 6, 9, and 12 hours post-exercise
TFAM gene expression. Transcription factor controlling the expression of mitochondrial-encoded genes.
before exercise and 1, 3, 6, 9, and 12 hours post-exercise
Change in TFAM protein content
Time Frame: before exercise and 1, 3, 6, 9, and 12 hours post-exercise
TFAM protein content
before exercise and 1, 3, 6, 9, and 12 hours post-exercise
Change in p53 mRNA expression
Time Frame: before exercise to 1, 3, 6, 9, and 12 hours post-exercise
p53 gene expression. Transcription factor involved in the control of mitochondrial biogenesis.
before exercise to 1, 3, 6, 9, and 12 hours post-exercise
Change in cytochrome c oxidase subunit 4 (COXIV) mRNA expression.
Time Frame: before exercise to 1, 3, 6, 9, and 12 hours post-exercise
COXIV gene expression. Nuclear encoded subunit of the electron transport chain complex 4 (COX)
before exercise to 1, 3, 6, 9, and 12 hours post-exercise
Change in COXI mRNA expression
Time Frame: before exercise to 1, 3, 6, 9, and 12 hours post-exercise
COXI gene expression. Mitochondrial encoded subunit of the electron transport chain complex IV (COX)
before exercise to 1, 3, 6, 9, and 12 hours post-exercise
Change in COXII mRNA expression
Time Frame: before exercise to 1, 3, 6, 9, and 12 hours post-exercise
COXII gene expression.Mitochondrial encoded subunit of the electron transport chain complex IV (COX).
before exercise to 1, 3, 6, 9, and 12 hours post-exercise
Change in nicotinamide adenine dinucleotide (NADH) subunit 1 (ND1) mRNA expression
Time Frame: before exercise and 1, 3, 6, 9, and 12 hours post-exercise
ND1 gene expression. Mitochondrial encoded subunit of the electron transport chain complex 1 (NADH dehydrogenase)
before exercise and 1, 3, 6, 9, and 12 hours post-exercise
Change in ND4 mRNA expression
Time Frame: before exercise to 1, 3, 6, 9, and 12 hours post-exercise
ND4 gene expression. Mitochondrial encoded subunit of the electron transport chain complex 1 (NADH dehydrogenase).
before exercise to 1, 3, 6, 9, and 12 hours post-exercise
Change in citrate synthase (CS) mRNA expression
Time Frame: before exercise to 1, 3, 6, 9, and 12 hours post-exercise
CS gene expression. The first rate limiting enzyme of the Kreb's cycle.
before exercise to 1, 3, 6, 9, and 12 hours post-exercise
Change in NRF-2 mRNA expression
Time Frame: before exercise and 1, 3, 6, 9, and 12 hours post-exercise
NRF-2 gene expression. Transcription factor involved in the control of mitochondrial biogenesis.
before exercise and 1, 3, 6, 9, and 12 hours post-exercise
Change in mitochondrial transcription factor B1 (TFB1M) mRNA expression
Time Frame: before exercise to 1, 3, 6, 9, and 12 hours post-exercise
TFB1M gene expression. Transcription factor controlling the expression of mitochondrial-encoded genes.
before exercise to 1, 3, 6, 9, and 12 hours post-exercise
Change in mitochondrial transcription factor B2 (TFB2M) mRNA expression
Time Frame: before exercise and 1, 3, 6, 9, and 12 hours post-exercise
TFB2M gene expression. Transcription factor controlling the expression of mitochondrial-encoded genes.
before exercise and 1, 3, 6, 9, and 12 hours post-exercise

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Brendon Gurd, PhD

Investigators

  • Principal Investigator: Brendon J. Gurd, PhD, School of Kinesiology and Health Studies

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2019

Primary Completion (Anticipated)

April 30, 2020

Study Completion (Anticipated)

April 30, 2020

Study Registration Dates

First Submitted

May 29, 2019

First Submitted That Met QC Criteria

June 4, 2019

First Posted (Actual)

June 5, 2019

Study Record Updates

Last Update Posted (Actual)

March 4, 2020

Last Update Submitted That Met QC Criteria

March 2, 2020

Last Verified

March 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • QMPL-TC-19

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe